Chronic myeloid leukemia: Room for improvement? by Baccarani, Michele et al.
haematologica | 2017; 102(7)
EDITORIALS
1131
Chronic myeloid leukemia: room for improvement?
Michele Baccarani,1 Fabrizio Pane,2 Gianantonio Rosti,3 Domenico Russo4 and Giuseppe Saglio5
1University of Bologna, and GIMEMA CML Working Party; 2University of Naples Federico II; 3Institute of Hematology "L. and A.
Seràgnoli", S.Orsola-Malpighi University Hospital, University of Bologna; 4Chair of Hematology and Unit of Blood diseases and Bone
Marrow Transplantation, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili Brescia and
5University of Torino, Italy 
E-mail: michele.baccarani@unibo.it    doi:10.3324/haematol.2017.166280
Following the introduction of imatinib and several othertyrosine kinase inhibitors (TKIs), the clinical scenario ofPhiladelphia chromosome-positive (Ph+) and BCR-
ABL1-positive (BCR-ABL1+) chronic myeloid leukemia
(CML) has changed almost completely.1 Although the num-
ber of studies is limited, and the follow up is short and some-
times defective, survival data are substantial; around 90% at
5 years, 89% at 6 years, 86% at 8 years, and 83-84% at 10
years2-10 (Table 1). Only 50% of deaths are due to the progres-
sion of leukemia, while 50% occur in remission and are due
to other causes which occasionally include treatment-related
toxicity and related complications. Relative survival analyses
have concluded that the life expectancy of a patient with
chronic phase (CP) CML, under proper TKI treatment, is now
very close or almost identical to the life expectancy of non-
leukemic, age-matched individuals.11,12 New drugs, both TKIs
and non-TKIs, are emerging. New, more sophisticated molec-
ular technologies are available. So, which problems remain to
be solved? Is there still room for improvement, and where?
There is still room for improvement for patients with
newly diagnosed accelerated phase (AP) and blastic phase
(BP) CML, and to some extent also for patients with high-risk
CP CML. The former account for 4% to 5% of all newly diag-
nosed patients.13 They respond to the TKI treatment, but the
extent of response is inferior, and their ultimate outcome is
still unclear.1 High-risk patients account for 10% to 25% of
newly diagnosed CP CML patients, depending on which risk
score is used, but even using Sokal, which is less selective and
includes many more patients than Euro, European Treatment
Outcome Study (EUTOS), and the new EUTOS long-term
survival score,14 the outcome of these patients is inferior, with
a reported survival of  83%-89% at 5-6 years and of  68% at
10 years7,10 (Table 1). In addition, the presence of clonal chro-
mosome abnormalities in Ph+ cells (CCA/Ph+) at baseline,
which occurs in 3% to 4% of patients, is a marker of an infe-
rior outcome.1 It is believed that all these patients (AP, BP,
Table 1. A summary of the outcome of treatment with TKIs of newly diagnosed CP CML patients. Only the studies reporting on more than 200 patients,
with a median follow-up observation of longer than 5 years, are listed. Notice the important differences in age and in the proportion of high-risk patients.
MD Anderson, German CML IV and GIMEMA are academic studies. The Swedish data are taken from a population-based registry. IRIS, ENESTnd and
DASISION are company-sponsored, registrative studies
Study IRIS2,10 MDA6 German GIMEMA5 ENESTnd8 DASISION9 ENESTnd8 DASISION9 SWEDEN3
CML IV4,7
First-line treatment Ima(A) (B) Ima (C) Ima (D) Ima 400 OD Ima Nil Das (E)
400 OD 300 OD 100 OD
No. pts 553 483 1536 559 282 260 282 259 717
Follow up, median 10.9 y 8.3 y 7.1 y 6.3 y 5.5 y 5.5 y 5.5 y 5.5 y 5.1 y
Follow up, missing % 20.1 NR 0.1 4.1 NR NR NR NR 17.8
Age, median 50 y (F) 53 y 52 y 46 y 49 y 47 y 46 y 60 y
High-risk  % 18 Sokal 7 Sokal 12 EUTOS 22 Sokal 28 Sokal 19 EURO 28 Sokal 19 EURO 32 Sokal
Progressions % 6.5 NR 6.7 5.7 7.4 7.3 3.5 4.6 NR
Deaths, total % 16.1 11.0 12.0 11.6 7.8 10.0 6.4 10.0 NR
Deaths, leukemia % 9.0 NR NR 5.7 5.7 6.5 2.1 3.5 NR
Deaths, other causes % 7.0 NR NR 5.9 2.1 3.5 4.2 6.6 NR
OS   5 years % 89 93 90 NR 92 90 94 91 83
OS   6 years % 88 NR NR 89 NR NR NR NR NA
OS   8 years % NR NR 86 NA NA NA NA NA NA
OS 10 years % 83 83 84 NA NA NA NA NA NA
OS low-risk % (at) 90 (10y) NR NR 94 (6y) 100 (5y) NR 97 (5y) NR 95 (5y)
OS high-risk
%  (at) 69 (10y) NR NR 83 (6y) 84 (5y) NR 89 (5y) NR 78 (5y)
(A) 400 mg once daily (OD). (B) Imatinib 400 mg OD (14% of patients), imatinib 400 mg twice daily (TD) (9%), imatinib 400 mg OD + pegylated interferon-α (33%), nilotinib (dose not
specified) 21%, dasatinib (dose not specified) 22%. (C) imatinib 400 mg OD (26.4% of patients), imatinib 400 mg OD + interferon-α (28.2%), imatinib 400 mg OD + low dose cytarabine
(10.3%), imatinib 400 mg OD after interferon-α (8.3%), imatinib 400 mg TD (27.3%). (D) imatinib 400 mg OD (76% of patients), imatinib 400 mg TD (24%). (E) No details, but TKIs for most
patients. "A small and decreasing proportion of elderly patients received first-line treatment with the intention of palliation (i.e., not including TKIs or upfront HSCT)".3 (F) 40.8% of
patients were less than 45 years old, 46.0% were 45 to 64 years old, 13.2% were ≥ 65 years old, no patient was ≥ 80 years old. NR: not reported; NA: not available; No.: number; pts: patients;
OS: overall survival. 
high-risk CP, CCA/Ph+) can benefit more from second- or
third-generation TKIs, and that some of them, in particular
those of younger age, are candidates for allogeneic stem
cell transplantation. However, much needed prospective,
specifically addressed trials are lacking. 
But is there still room for improvement for the 80% to
90% of patients who become optimal responders and
have a normal life expectancy? TKIs cannot prolong life,
but their proper use can help to improve the quality of life
without precluding the achievement of a remission that
remains stable even after treatment discontinuation (treat-
ment-free remission, TFR). Concerning the quality of life,
many studies report that the side effects or toxic effects of
TKIs were “manageable”, could be tolerated, and did not
impel a change of TKI. Typically, such studies were
designed to limit the switch from one TKI to another, and
were analyzed more to define the tolerability profile of a
specific TKI than to assess the quality of life of the
patients. We suggest that in the case of so-called “manage-
able” side effects, mild or recurrent, that impair the daily
life of a patient, more consideration should be given to a
change of the drug and also to a change of the dose, pro-
vided that an optimal response is maintained. At times a
patient-adapted policy, that is a policy adapted to side
effects and to response, can be more convenient. For that
purpose, trials may not be necessary, but a careful long-
term observation will be important to control overall how
patients adapt to side effects and to pick up on the so-
called unexpected adverse events. 
TFR is an acronym that fully expresses the success of
therapy, combining the perception of cure, a normal life
expectancy, no treatment-related side effects and compli-
cations, independence from drugs, in addition to a proper
use of the financial resources of health systems that are
more and more challenged by the introduction of new and
effective, but also expensive drugs.15-17 It is expected that a
more widespread use of second-generation TKIs in first-
line treatment would result in increased TFR. However,
evidence is still missing as there are no studies reporting
on the benefit (the TFR rate) and the cost (toxicity) of a
policy of imatinib use vs. a policy of the use of second-gen-
eration TKIs, either in early or late first- or second-line
therapy.17 Such studies require time, patience and
resources, but are necessary in order to move from expec-
tation to evidence. Gruppo Italiano Malattie EMatologiche
dell'Adulto (GIMEMA) and the Haemato Oncology
Foundation for Adults in the Netherlands (HOVON) are
currently running a trial of first-line nilotinib vs. first-line
imatinib therapy with a switch to nilotinib in the event of
less than optimal response, with the TFR rate at 5 years
being the primary endpoint.18 More than five years will be
required to obtain answers from this study. Furthermore,
the choice between continuing treatment indefinitely and
no treatment at all may be challenged and alternative poli-
cies are currently being tested, either of partial, intermit-
tent treatment,19,20 or of graded discontinuation.21 For the
time being we must acknowledge that any recommenda-
tion concerning the policy of treatment regarding TFR is
not yet evidence-based. In all likelihood, the best policy
does not exist, and different policies may be successful in
different situations.
Notwithstanding the fact that the treatment and the
modalities of treatment for TFR are still an issue for
research, it should not be overlooked that treatment dis-
continuation and TFR are already a reality in practice, and
are the goal of more and more patients. There are solid
data showing that treatment discontinuation after five or
more years of TKIs, and after one or more years of deep
molecular response (MR), such as MR 4.0 (BCR-ABL1 ≤
0.01% on the international scale), and particularly MR 4.5
(BCR-ABL1 ≤  0.0032%, on the international scale) results
in a rate of TFR of 50% or more, and that in the event of
molecular relapse the resumption of treatment brings all
patients back to molecular remission.15,16,22,23
In summary, once a deep MR is achieved, and provided
that careful molecular monitoring is assured, no patient
will die of leukemia because of treatment discontinuation,
and 50% will enjoy a treatment-free life. Therefore, we
suggest that both the possibilities and the problems of
treatment discontinuation should be discussed not only
with all the patients who fit the current, provisional eligi-
bility criteria for discontinuation, but also with newly
diagnosed patients.
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Mantle cell lymphoma (MCL) is nowadays recog-nized as a spectrum of diseases, characterized bysignificantly different treatment responses and
outcomes. Some predictors of clinical and biological out-
come have been established and validated over recent
years, and these are either assessable at baseline (mainly
MCL international prognostic indexes, Ki-67 proliferative
index and genomic aberrations) or during treatment (func-
tional imaging and minimal residual disease, MRD). MRD
is defined as the minimal traceable persistence of lym-
phoma cells after a successful treatment. Many methods
to monitor MRD have been published; however, the most
sensitive and the most commonly used and best standard-
ized approach in MCL is represented by the allele-specific
oligonucleotide (ASO) quantitative polymerase chain reac-
tion (qPCR) method.1 The most relevant prospective trials
investigating the impact of MRD on MCL patient out-
come are listed in Table 1A.
The clinical role of MRD analysis in MCL is reflected
according to four major aspects (Figure 1).
MRD provides early feedback on the efficacy of the clearance
of different induction regimens. The dynamics and stability of
tumor shrinkage after treatment can currently be precisely
tracked by MRD kinetics; these data might be useful as an
early in vivo predictor of the anti-lymphoma effect of a
new compound.6,9,10 Moreover, MRD can be used as a sur-
rogate end point for progression-free survival (PFS) com-
paring the efficacy of different treatments in randomized
trials, thus accelerating the development, and eventually
the approval, of new drugs. For example, the superior out-
come of the cytarabine-containing experimental arm of
the “MCL Younger” phase III trial of the European MCL
Network was heralded by a higher rate of MRD clearance
many years before publication of the final results.5,15
MRD can provide an early prediction of disease recurrence.
Even in the context of an incurable disease like MCL, the
deepness of treatment response measured by MRD wide-
ly reflects patient outcome in large, prospective trials.3-5
The predictive role of MRD analysis in MCL was con-
firmed in different patient subsets (both younger and eld-
erly), treatment strategies (autologous transplantation and
conventional immuno-chemotherapy), tissues (bone mar-
row and peripheral blood) and time points (end of induc-
tion and during maintenance treatment).4
MRD allows for risk stratification of patients after treatment.
MRD describes the efficacy of therapy and presence of even
minimal, resistant tumor clones; thus, this approach identi-
fies patients at higher risk of recurrence after an apparently
successful treatment. Actually, persistence of MRD positiv-
ity or recurrence after a transient MRD negativity precedes
clinical relapse, with a median time lag of 18 months.16
MRD might drive pre-emptive treatment.As MRD positivity
predicts upcoming clinical relapse, this approach can guide
treatment tailoring, with the aim of preventing or delaying
overt disease progression. In a number of prospective
reports, a pre-emptive rituximab treatment of MRD posi-
tive patients was able to reconvert them to MRD negativ-
ity, with the possibility of also prolonging their PFS.8,17
Nevertheless, some limitations still hamper the wide-
spread use of MRD analysis in clinical routine. The two
major obstacles as far as methodology is concerned are the
need for patient-specific primers and standardization
issues. At present, the ASO-qPCR strategy relies upon
either the clonal rearrangement of the IGH gene or the
BCL-1/IGH rearrangement, derived from the t(11;14);
both of these DNA sequences are unique for each B-cell
clone, so individual primers are required for each patient
to guarantee a reliable sensitivity. Thus a “one-fits-all”
easy-to-use in vitro diagnostic medical device (IVD-kit) is
not conceivable in MRD diagnostics so far, and access to
an experienced and dedicated laboratory is mandatory. In
addition, a rigorous standardization of the methods is
essential in order to provide comparable results among dif-
ferent centers. Only selected laboratories across Europe
